CN114159381A - Scald ointment and preparation method and application thereof - Google Patents
Scald ointment and preparation method and application thereof Download PDFInfo
- Publication number
- CN114159381A CN114159381A CN202111655881.7A CN202111655881A CN114159381A CN 114159381 A CN114159381 A CN 114159381A CN 202111655881 A CN202111655881 A CN 202111655881A CN 114159381 A CN114159381 A CN 114159381A
- Authority
- CN
- China
- Prior art keywords
- parts
- scald
- scald ointment
- camphor
- ointment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010053615 Thermal burn Diseases 0.000 title claims abstract description 67
- 239000002674 ointment Substances 0.000 title claims abstract description 46
- 238000002360 preparation method Methods 0.000 title abstract description 7
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 claims abstract description 26
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 claims abstract description 26
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 claims abstract description 26
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims abstract description 19
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims abstract description 15
- 229940041616 menthol Drugs 0.000 claims abstract description 15
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 13
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 claims abstract description 13
- 239000005844 Thymol Substances 0.000 claims abstract description 13
- FPVRUILUEYSIMD-RPRRAYFGSA-N [(8s,9r,10s,11s,13s,14s,16r,17r)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(OC(C)=O)[C@@]1(C)C[C@@H]2O FPVRUILUEYSIMD-RPRRAYFGSA-N 0.000 claims abstract description 13
- 229950000210 beclometasone dipropionate Drugs 0.000 claims abstract description 13
- 229960003657 dexamethasone acetate Drugs 0.000 claims abstract description 13
- 229960001047 methyl salicylate Drugs 0.000 claims abstract description 13
- 229960000790 thymol Drugs 0.000 claims abstract description 13
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims abstract description 11
- 241000723346 Cinnamomum camphora Species 0.000 claims abstract description 11
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229940116229 borneol Drugs 0.000 claims abstract description 11
- 229930008380 camphor Natural products 0.000 claims abstract description 11
- 229960000846 camphor Drugs 0.000 claims abstract description 11
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229940085790 synthetic camphor Drugs 0.000 claims abstract description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 39
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 24
- 239000000463 material Substances 0.000 claims description 21
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 16
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 claims description 16
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 16
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 16
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 16
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 8
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 8
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 claims description 8
- 229920002125 Sokalan® Polymers 0.000 claims description 8
- 235000021355 Stearic acid Nutrition 0.000 claims description 8
- 229960001631 carbomer Drugs 0.000 claims description 8
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 8
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims description 8
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims description 8
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 8
- 229940074045 glyceryl distearate Drugs 0.000 claims description 8
- 229940075507 glyceryl monostearate Drugs 0.000 claims description 8
- 229940057995 liquid paraffin Drugs 0.000 claims description 8
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 8
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 8
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 8
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 8
- 239000008117 stearic acid Substances 0.000 claims description 8
- -1 liquid paraffin Chemical compound 0.000 claims description 7
- 239000003871 white petrolatum Substances 0.000 claims description 7
- 229960000541 cetyl alcohol Drugs 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 4
- 229940025250 camphora Drugs 0.000 claims description 4
- 239000010238 camphora Substances 0.000 claims description 4
- 229960005150 glycerol Drugs 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 2
- 229940083608 sodium hydroxide Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 abstract description 5
- 230000035876 healing Effects 0.000 abstract description 3
- 206010052428 Wound Diseases 0.000 description 13
- 208000027418 Wounds and injury Diseases 0.000 description 13
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 238000007723 die pressing method Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 239000004065 semiconductor Substances 0.000 description 2
- 208000032544 Cicatrix Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940124274 edetate disodium Drugs 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 231100000075 skin burn Toxicity 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A61K31/125—Camphor; Nuclear substituted derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/618—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to the technical field of scald ointments, in particular to a scald ointment and a preparation method and application thereof; the scald ointment comprises the following components in parts by weight: 30-55 parts of menthol, 50-60 parts of synthetic camphor, 20-35 parts of methyl salicylate, 2-8 parts of borneol, 1-5 parts of thymol, 0.05-1 part of beclomethasone dipropionate, 0.1-2 parts of dexamethasone acetate and 2-16 parts of camphor. The scald ointment can prevent infection of burn and scald wound, and promote healing of burn and scald wound.
Description
Technical Field
The invention relates to the technical field of scald ointments, and particularly relates to a scald ointment as well as a preparation method and application thereof.
Background
The function of the skin is to prevent bacterial erosion and infection of the human body, regulate the body temperature and discharge body fluid and the like, is an organ with the largest area of the human body, and inevitably causes skin damage in daily life, wherein burn and scald are more difficult to treat than common wounds, and especially the treatment of large-area skin burn and scald is always a medical problem. After the burn and scald occur, the gas permeability of the skin can be influenced, loss of tissue fluid and body fluid and loss of electrolyte and protein can be caused, and contact rejection of tissues can be damaged, so that effective treatment should be given in time after the burn and scald occur to prevent infection of the burn and scald wound.
Disclosure of Invention
The invention aims to provide a scald ointment which can prevent infection of a burn wound and a scald wound and enable the burn wound and the scald wound to heal quickly.
In order to achieve the above object, the present invention provides a scald ointment, which comprises the following components by weight:
30-55 parts of menthol, 50-60 parts of synthetic camphor, 20-35 parts of methyl salicylate, 2-8 parts of borneol, 1-5 parts of thymol, 0.05-1 part of beclomethasone dipropionate, 0.1-2 parts of dexamethasone acetate and 2-16 parts of camphor.
According to the second aspect of the invention, the preparation method of the scald ointment comprises the step of uniformly mixing the menthol, the synthetic camphor, the methyl salicylate, the borneol, the thymol, the beclomethasone dipropionate, the dexamethasone acetate, the camphor, the menthol and the auxiliary materials according to the proportion to obtain the scald ointment.
In a third aspect, the invention provides an application of the scald ointment in treating burns and/or scalds.
The scald ointment provided by the invention can prevent the infection of the burn and scald wound, promote the recovery of the affected part, quickly relieve pain, quickly heal the burn and scald wound and does not pollute clothes.
Detailed Description
The endpoints of the ranges and any values disclosed herein are not limited to the precise range or value, and such ranges or values should be understood to encompass values close to those ranges or values. For ranges of values, between the endpoints of each of the ranges and the individual points, and between the individual points may be combined with each other to give one or more new ranges of values, and these ranges of values should be considered as specifically disclosed herein.
According to a first aspect of the present invention, the present invention provides a scald ointment, comprising, by weight:
30-55 parts of menthol, 50-60 parts of synthetic camphor, 20-35 parts of methyl salicylate, 2-8 parts of borneol, 1-5 parts of thymol, 0.05-1 part of beclomethasone dipropionate, 0.1-2 parts of dexamethasone acetate and 2-16 parts of camphor. The scald ointment provided by the invention can prevent the burn and scald wound surface from being infected, promote the recovery of the affected part and enable the burn and scald wound surface to heal quickly.
According to a preferred embodiment of the present invention, the scald ointment comprises, in parts by weight:
42-48 parts of menthol, 54-58 parts of synthetic camphor, 27-32 parts of methyl salicylate, 3-6 parts of borneol, 2-4 parts of thymol, 0.05-0.2 part of beclomethasone dipropionate, 0.1-1 part of dexamethasone acetate and 7-12 parts of camphor.
According to a preferred embodiment of the present invention, the scald ointment is a cream.
According to a preferred embodiment of the invention, the scald ointment further comprises an auxiliary material, and the auxiliary material content is 1600-1900 parts by weight.
According to a preferred embodiment of the invention, the auxiliary materials comprise, by mass percentage, 15-25 wt% of octadecanol stearic acid, 2-7 wt% of white vaseline, 5-15 wt% of glyceryl monostearate, 2-6 wt% of glycerol, 0.1-1 wt% of sodium hydroxide, 5-8 wt% of ethylparaben, 2-8 wt% of cetyl alcohol, 2-6 wt% of liquid paraffin, 10-20 wt% of glyceryl distearate, 10-20 wt% of polyoxyl (40) stearate, 0.5-2 wt% of disodium edetate, 1-2 wt% of carbomer, 1-2 wt% of sodium bicarbonate and 8-20 wt% of water.
The scald ointment with the properties can achieve the aim of the invention, the invention has no special requirement on the preparation method, and the invention provides the preparation method of the scald ointment, which comprises the following steps:
mixing Mentholum, synthetic Camphora, methyl salicylate, Borneolum Syntheticum, thymol, beclomethasone dipropionate, dexamethasone acetate, Camphora, Mentholum and the adjuvants uniformly according to a certain proportion to obtain scald ointment.
According to a preferred embodiment of the present invention, the method for preparing the scald ointment comprises the following steps:
(1) uniformly mixing 25-40 parts of menthol, 50-60 parts of synthetic camphor, 20-35 parts of methyl salicylate, 2-8 parts of borneol, 1-5 parts of thymol, 0.05-1 part of beclomethasone dipropionate and 800-950 parts of first auxiliary material according to a proportion to obtain a component A;
the first auxiliary materials comprise octadecanol stearic acid, white vaseline, glyceryl monostearate, glycerol, sodium hydroxide, ethylparaben, disodium edetate, carbomer and water;
(2) uniformly mixing 0.1-2 parts of dexamethasone acetate, 2-16 parts of camphor, 5-15 parts of menthol and 800-950 parts of second auxiliary material according to the proportion to obtain a component B;
the second adjuvant comprises cetyl alcohol, liquid paraffin, glycerol, glyceryl distearate, polyoxyl (40) stearate, sodium bicarbonate and water.
(2) According to the mass ratio of the component A: and (4) mixing the two components uniformly according to the ratio of 4-6: 6-4.
According to a preferred embodiment of the present invention, octadecanol, stearic acid, 30-50 wt%, white vaseline, 4-14 wt%, glyceryl monostearate, 10-30 wt%, glycerol, 2-6 wt%, sodium hydroxide, 0.2-2 wt%, ethylparaben, 10-16 wt%, edetate disodium, 1-4 wt%, carbomer, 2-4 wt% and water, 8-20 wt%.
According to a preferred embodiment of the invention, the content of the hexadecanol is 10-16 wt%, the liquid paraffin is 4-12 wt%, the glycerol is 2-6 wt%, the glyceryl distearate is 20-40 wt%, the polyoxyl (40) stearate is 20-40 wt%, the sodium bicarbonate is 2-4 wt% and the water is 8-20 wt%.
In a third aspect, the invention provides an application of the scald ointment in treating burns and scalds.
The present invention will be described in detail below by way of examples.
Example 1
(1) The auxiliary materials comprise 16 wt% of octadecanol stearic acid, 3 wt% of white vaseline, 14.5 wt% of glyceryl monostearate, 4 wt% of glycerol, 0.2 wt% of sodium hydroxide, 6 wt% of ethylparaben, 3 wt% of hexadecanol, 3 wt% of liquid paraffin, 17.5 wt% of glyceryl distearate, 17 wt% of polyoxyl (40) stearate, 1 wt% of disodium edetate, 1 wt% of carbomer, 1 wt% of sodium bicarbonate and 12.8 wt% of water in percentage by mass, and the auxiliary materials are obtained by uniformly mixing the components in proportion;
(2) uniformly mixing 45 parts of menthol, 56 parts of synthetic camphor, 30 parts of methyl salicylate, 5 parts of borneol, 2.5 parts of thymol, 0.1 part of beclomethasone dipropionate, 0.75 part of dexamethasone acetate, 10 parts of camphor and 1850.65 parts of auxiliary materials to obtain the scald ointment.
Example 2
(1) Uniformly mixing 35 parts of menthol, 56 parts of synthetic camphor, 30 parts of methyl salicylate, 5 parts of borneol, 2.5 parts of thymol, 0.1 part of beclomethasone dipropionate and 871.4 parts of first auxiliary material to obtain a component A; the first auxiliary material comprises 32 wt% of octadecanol stearic acid, 6 wt% of white vaseline, 29 wt% of glyceryl monostearate, 4 wt% of glycerol, 0.4 wt% of sodium hydroxide, 12 wt% of ethylparaben, 2 wt% of disodium edetate, 2 wt% of carbomer and 12.6 wt% of water which are uniformly mixed according to the proportion;
(2) uniformly mixing 0.1-2 parts of dexamethasone acetate, 2-16 parts of camphor, 5-15 parts of menthol and 800-950 parts of second auxiliary material to obtain a component B; the second auxiliary material comprises, by mass, 6 wt% of cetyl alcohol, 6 wt% of liquid paraffin, 4 wt% of glycerol, 35 wt% of glyceryl distearate, 34 wt% of polyoxyl (40) stearate, 2% of sodium bicarbonate and 13 wt% of water which are uniformly mixed according to the proportion;
(3) according to the mass ratio, the component A: and uniformly mixing the two components in a ratio of 5:5 to obtain the scald ointment.
Typical cases are:
1. workers in Jiangxi Delichi semiconductor company scald the wrist by means of two-hundred-degree temperature die pressing by means of a die pressing machine, the scald ointment provided by the embodiment 2 of the invention is applied in time after bubbling, the water bubbles disappear after one hour, the scald ointment is applied for three times a day, and the wound is healed after 5 days without scars.
2. After a certain die repairing and pressing machine of winter plum in 2018 of Jiangxi Delicheng semiconductor company overhauls and scalds the scald surface of the arm for a few centimeters by using the machine, and the scald ointment provided by the embodiment 2 of the invention is applied after ten minutes, the skin is slowly turned into light red and is coated with the medicine, the scald ointment is applied only once, and the wound is exuviated and healed without scar after 4 days.
3. The grandeur of a nephew clock of the inventor is successively spotted with the joss stick to scald the arm carelessly, the scald ointment provided by the invention in the embodiment 2 is applied after the dry and dry wound is cleaned, and the scald ointment is applied for the second time in the morning and heals after 4 days.
Tests show that the healing effect of the scald ointment prepared in the example 2 is better than that of the scald ointment prepared in the example 1, the healing time of the scald ointment prepared in the example 2 is mainly shorter than that of the scald ointment prepared in the example 1, and scalds can be healed more quickly.
The preferred embodiments of the present invention have been described above in detail, but the present invention is not limited thereto. Within the scope of the technical idea of the invention, many simple modifications can be made to the technical solution of the invention, including combinations of various technical features in any other suitable way, and these simple modifications and combinations should also be regarded as the disclosure of the invention, and all fall within the scope of the invention.
Claims (10)
1. The scald ointment is characterized by comprising the following components in parts by weight:
30-55 parts of menthol, 50-60 parts of synthetic camphor, 20-35 parts of methyl salicylate, 2-8 parts of borneol, 1-5 parts of thymol, 0.05-1 part of beclomethasone dipropionate, 0.1-2 parts of dexamethasone acetate and 2-16 parts of camphor.
2. The scald ointment of claim 1, wherein the scald ointment comprises, in parts by weight:
42-48 parts of menthol, 54-58 parts of synthetic camphor, 27-32 parts of methyl salicylate, 3-6 parts of borneol, 2-4 parts of thymol, 0.05-0.2 part of beclomethasone dipropionate, 0.1-1 part of dexamethasone acetate and 7-12 parts of camphor.
3. The scald ointment of claim 1 or 2, wherein the scald ointment is a cream.
4. The scald ointment as claimed in any one of claims 1 to 3, further comprising an auxiliary material in an amount of 1600-1900 parts by weight.
5. The scald ointment of claim 4, wherein the auxiliary materials comprise, by mass, 15-25 wt% of octadecanol, stearic acid, 2-7 wt% of albolene, 5-15 wt% of glyceryl monostearate, 2-6 wt% of glycerol, 0.1-1 wt% of sodium hydroxide, 5-8 wt% of ethylparaben, 2-8 wt% of cetyl alcohol, 2-6 wt% of liquid paraffin, 10-20 wt% of glyceryl distearate, 10-20 wt% of polyoxyl (40) stearate, 0.5-2 wt% of disodium edetate, 1-2 wt% of carbomer, 1-2 wt% of sodium bicarbonate and 8-20 wt% of water.
6. The method for preparing the scald ointment as set forth in any one of claims 1 to 5, comprising the steps of:
mixing Mentholum, synthetic Camphora, methyl salicylate, Borneolum Syntheticum, thymol, beclomethasone dipropionate, dexamethasone acetate, Camphora, Mentholum and the adjuvants uniformly according to a certain proportion to obtain scald ointment.
7. The method of claim 6, wherein the method comprises the steps of:
(1) uniformly mixing 25-40 parts of menthol, 50-60 parts of synthetic camphor, 20-35 parts of methyl salicylate, 2-8 parts of borneol, 1-5 parts of thymol, 0.05-1 part of beclomethasone dipropionate and 800-950 parts of first auxiliary material according to a proportion to obtain a component A;
the first auxiliary materials comprise octadecanol stearic acid, white vaseline, glyceryl monostearate, glycerol, sodium hydroxide, ethylparaben, disodium edetate, carbomer and water;
(2) uniformly mixing 0.1-2 parts of dexamethasone acetate, 2-16 parts of camphor, 5-15 parts of menthol and 800-950 parts of second auxiliary material according to the proportion to obtain a component B;
the second adjuvant comprises cetyl alcohol, liquid paraffin, glycerol, glyceryl distearate, polyoxyl (40) stearate, sodium bicarbonate and water.
(2) According to the mass ratio of the component A: and (4) mixing the two components uniformly according to the ratio of 4-6: 6-4.
8. The production method according to claim 7, wherein,
the first auxiliary material comprises the following components in percentage by mass: 30-50 wt% of octadecanol stearic acid, 4-14 wt% of white vaseline, 10-30 wt% of glyceryl monostearate, 2-6 wt% of glycerol, 0.2-2 wt% of sodium hydroxide, 10-16 wt% of ethylparaben, 1-4 wt% of disodium edetate, 2-4 wt% of carbomer and 8-20 wt% of water.
9. The production method according to claim 7, wherein,
the second auxiliary material comprises, by mass, 10-16 wt% of cetyl alcohol, 4-12 wt% of liquid paraffin, 2-6 wt% of glycerol, 20-40 wt% of glyceryl distearate, 20-40 wt% of polyoxyl (40) stearate, 2-4 wt% of sodium bicarbonate and 8-20 wt% of water.
10. Use of the scald ointment of any one of claims 1-5 in the treatment of burns and/or scalds.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111655881.7A CN114159381A (en) | 2021-12-30 | 2021-12-30 | Scald ointment and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111655881.7A CN114159381A (en) | 2021-12-30 | 2021-12-30 | Scald ointment and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114159381A true CN114159381A (en) | 2022-03-11 |
Family
ID=80488677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111655881.7A Pending CN114159381A (en) | 2021-12-30 | 2021-12-30 | Scald ointment and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114159381A (en) |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1086999A (en) * | 1993-03-20 | 1994-05-25 | 漳州市香料总厂 | External cream for treating common skin diseases and preparation method thereof |
| CN1121416A (en) * | 1994-12-29 | 1996-05-01 | 张志学 | Multi-function ointment for scald |
| JP2002121152A (en) * | 2000-10-13 | 2002-04-23 | Chugai Pharmaceut Co Ltd | Antiphlogistic sedative medicine for external use |
| CN1562140A (en) * | 2004-04-14 | 2005-01-12 | 李训峰 | Chinese-western combined medicine for treating burn and scald and other external wound |
| CN1650995A (en) * | 2004-12-01 | 2005-08-10 | 陈立德 | Itching relieving medicament |
| CN101288672A (en) * | 2007-04-18 | 2008-10-22 | 陈成彬 | Medicine for treating dermatopathy and its preparing process |
| CN105287700A (en) * | 2015-10-21 | 2016-02-03 | 烟台宝肤灵生物科技有限公司 | Medicine for treating mosquito bites, burns and scalds, and skin diseases and preparation method of medicine |
| CN108992451A (en) * | 2018-07-09 | 2018-12-14 | 漳州无极药业有限公司 | A kind of emulsifiable paste and preparation method thereof with anti-inflammatory anti-itch antibiotic effect |
| CN110237122A (en) * | 2019-06-17 | 2019-09-17 | 雷春明 | A kind of external drug and its preparation method and application |
-
2021
- 2021-12-30 CN CN202111655881.7A patent/CN114159381A/en active Pending
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1086999A (en) * | 1993-03-20 | 1994-05-25 | 漳州市香料总厂 | External cream for treating common skin diseases and preparation method thereof |
| CN1121416A (en) * | 1994-12-29 | 1996-05-01 | 张志学 | Multi-function ointment for scald |
| JP2002121152A (en) * | 2000-10-13 | 2002-04-23 | Chugai Pharmaceut Co Ltd | Antiphlogistic sedative medicine for external use |
| CN1562140A (en) * | 2004-04-14 | 2005-01-12 | 李训峰 | Chinese-western combined medicine for treating burn and scald and other external wound |
| CN1650995A (en) * | 2004-12-01 | 2005-08-10 | 陈立德 | Itching relieving medicament |
| CN101288672A (en) * | 2007-04-18 | 2008-10-22 | 陈成彬 | Medicine for treating dermatopathy and its preparing process |
| CN105287700A (en) * | 2015-10-21 | 2016-02-03 | 烟台宝肤灵生物科技有限公司 | Medicine for treating mosquito bites, burns and scalds, and skin diseases and preparation method of medicine |
| CN108992451A (en) * | 2018-07-09 | 2018-12-14 | 漳州无极药业有限公司 | A kind of emulsifiable paste and preparation method thereof with anti-inflammatory anti-itch antibiotic effect |
| CN110237122A (en) * | 2019-06-17 | 2019-09-17 | 雷春明 | A kind of external drug and its preparation method and application |
Non-Patent Citations (1)
| Title |
|---|
| 杨宗城等: "《万事不求人 家庭安全篇》", 中国国际广播出版社, pages: 168 - 169 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Widgerow et al. | New innovations in scar management | |
| CN108653129B (en) | Skin dressing containing natural plant anti-allergy composition | |
| JP5965393B2 (en) | Kit of parts for treating and / or preventing skin ulcers | |
| CN114699513A (en) | Preparation method of scar gel containing yeast recombinant collagen | |
| CN112354005B (en) | Dressing for promoting healing of burn and scald wound surfaces and preparation method thereof | |
| CN114099604A (en) | Biological dressing with scar preventing function and preparation method thereof | |
| Soni et al. | Effect of ethanolic extract of cinnamomum tamala leaves on wound healing in stz induced diabetes in rats | |
| CN114159381A (en) | Scald ointment and preparation method and application thereof | |
| CN113662959B (en) | Composition for preventing and/or repairing skin damage and application thereof | |
| WO2016115768A1 (en) | Burn ointment for promoting tissue regeneration and skin growth, and preparation method therefor | |
| Satish et al. | Evaluation of Wound Healing Activity of Catharanthus Roseus Aqueous Extract in Adult Albino Rats.(2021) | |
| CN108853369B (en) | Preparation method and application of natural plant antibacterial liquid PAMs hydrogel patch | |
| US10232004B2 (en) | Pharmaceutical composition based on Centella asiatica (Hydrocotyle asiatica L.) for the treatment of lower limb ulcers | |
| RU2355411C1 (en) | Wound- healing ointment | |
| RU2674445C1 (en) | Alcohol spray for external use | |
| CN109498562B (en) | Emergency burn care solution and preparation method thereof | |
| RU2358757C1 (en) | Persistent wound healing approach in patients suffering from pancreatic diabetes | |
| WO2019080115A1 (en) | Long-acting sustained-release traditional chinese medicine cold compress for treating skin ulcer | |
| CN111632111A (en) | Yellow medicinal powder for treating burns, scalds and wounds | |
| Aswany et al. | A Concise Review on Scarless Wound Healing | |
| KR100289906B1 (en) | Dermatological composition | |
| Rathod et al. | A CASE REPORT OF SKIN GRAFT IN MANAGEMENT OF DIABETIC WOUND ALONG WITH PANCHVALKAL KASHAY DHAVAN | |
| CN117045844A (en) | Dressing containing polysaccharide and preparation method and application thereof | |
| Sonani et al. | KATUPILACHURNA IN THE MANAGEMENT OF DUSTAVRANA WSR TO VENOUS ULCER: A SINGLE CASE REPORT | |
| CN115869374A (en) | Preparation method of nasal cold compress suspension |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |